FOXM1 and colorectal cancer: Similar to esophageal cancer, STL001 in combination with 5-FU therapy remarkably decreased 5-FU-induced FOXM1 levels and significantly enhanced the sensitivity of colorectal cancer cells (HCT-116 and FET) to the cytotoxic effects of 5-FU therapy (Fig. 6A).